このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Changes in Body Composition When Ingesting a Dairy Compound Enriched With Leucine (LEUCI)

2020年5月20日 更新者:Francisco Javier López Román、Universidad Católica San Antonio de Murcia

Randomized Clinical Trial on Changes in Body Composition When Ingesting a Dairy Compound Enriched With Leucine Daily for 3 Months

Controlled clinical trial, randomized by strata (sex and period of the study), with 6 parallel branches to the study depending on the type of product consumed and the type of physical exercise program performed, double-blind masked for the consumption of the product and single-center.

調査の概要

詳細な説明

The subjects that meet the selection criteria will make a total of seven visits to the research laboratory (two of them to collect product) and will carry out the pre-established tests in the protocol. Subsequently, a statistical analysis will be carried out with the variables measured in the study to obtain results.

研究の種類

介入

入学 (実際)

142

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Murcia、スペイン、30107
        • Catholic University of Murcia

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

55年~70年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Subjects of both sexes with age between 55-70 years.
  • Body mass index less than 35.
  • Subjects who have given written informed consent to participate in the study.

Exclusion Criteria:

  • Consumption during the 6 months prior to the study of functional food enriched with leucine or nutritional supplement based on protein concentrate or that presents in its chemical composition leucine.
  • Presence of absolute or relative contraindications ruled by the American College of Sports Medicine (ACSM, 1995), during the performance of stress tests.
  • Presence of chronic diseases that prevent the performance of a physical exercise program or an exercise test (disabling arthropathies, moderate / severe chronic lung diseases, ischemic heart disease under treatment, arrhythmias, etc).
  • Abuse in the ingestion of alcohol.
  • Present hypersensitivity or intolerance to any of the components of the products under study.
  • Inability to understand informed consent.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Experimental group 1 (TS + placebo)

Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.

Daily consumption for 3 months of placebo milk.

Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).

In addition, 5 of the arms perform physical activity training

実験的:Experimental group 2 (TS + leucine)

Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.

Daily consumption for 3 months of milk enriched with leucine.

Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).

In addition, 5 of the arms perform physical activity training

実験的:Experimental group 3 (HRC + placebo)

Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.

Daily consumption for 3 months of placebo milk.

Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).

In addition, 5 of the arms perform physical activity training

実験的:Experimental group 4 (HRC + leucine)

Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.

Daily consumption for 3 months of milk enriched with leucine.

Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).

In addition, 5 of the arms perform physical activity training

実験的:Experimental group 5 (no physical exercise + leucine)

The subjects will not carry out any type of physical activity.

Daily consumption for 3 months of milk enriched with leucine.

Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).

In addition, 5 of the arms perform physical activity training

介入なし:Control (no physical exercise + placebo)

The subjects will not carry out any type of physical activity.

Daily consumption for 3 months of placebo milk.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Muscle mass
時間枠:Change of this measurement at 3 months.
Dual X-ray absorptiometry (DEXA)
Change of this measurement at 3 months.
Total fat mass
時間枠:Change of this measurement at 3 months.
Dual X-ray absorptiometry (DEXA)
Change of this measurement at 3 months.
Total fat free mass
時間枠:Change of this measurement at 3 months.
Dual X-ray absorptiometry (DEXA)
Change of this measurement at 3 months.
Fat free mass on upper limb
時間枠:Change of this measurement at 3 months.
Dual X-ray absorptiometry (DEXA)
Change of this measurement at 3 months.
Upper limb fat mass
時間枠:Change of this measurement at 3 months.
Dual X-ray absorptiometry (DEXA)
Change of this measurement at 3 months.
Fat-free mass in the lower limb
時間枠:Change of this measurement at 3 months.
Dual X-ray absorptiometry (DEXA)
Change of this measurement at 3 months.
Lower limb fat mass
時間枠:Change of this measurement at 3 months.
Dual X-ray absorptiometry (DEXA)
Change of this measurement at 3 months.

二次結果の測定

結果測定
メジャーの説明
時間枠
Elbow extension
時間枠:This measurement is carried out in each of the groups, at the beginning (baseline) and at 3 months (end).
Upper limb isokinetic dynamometry. The angular velocities used were 60 ° · s-1 and 270 ° · s-1. The variables measured for each of them were maximum isokinetic torque, maximum isokinetic torque in relation to body weight, total work and average power.
This measurement is carried out in each of the groups, at the beginning (baseline) and at 3 months (end).
Elbow flexion
時間枠:This measurement is carried out in each of the groups, at the beginning (baseline) and at 3 months (end).
Upper limb isokinetic dynamometry. The angular velocities used were 60 ° · s-1 and 270 ° · s-1. The variables measured for each of them were maximum isokinetic torque, maximum isokinetic torque in relation to body weight, total work and average power.
This measurement is carried out in each of the groups, at the beginning (baseline) and at 3 months (end).
Knee extension
時間枠:This measurement is carried out in each of the groups, at the beginning (baseline) and at 3 months (end).
Lower limb isokinetic dynamometry. The angular velocities used were 60 ° · s-1 and 270 ° · s-1. The variables measured for each of them were maximum isokinetic torque, maximum isokinetic torque in relation to body weight, total work and average power.
This measurement is carried out in each of the groups, at the beginning (baseline) and at 3 months (end).
Knee flexion
時間枠:This measurement is carried out in each of the groups, at the beginning (baseline) and at 3 months (end).
Lower limb isokinetic dynamometry. The angular velocities used were 60 ° · s-1 and 270 ° · s-1. The variables measured for each of them were maximum isokinetic torque, maximum isokinetic torque in relation to body weight, total work and average power.
This measurement is carried out in each of the groups, at the beginning (baseline) and at 3 months (end).
Blood samples: Glycid metabolism and lipid metabolism.
時間枠:Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 3 months.
Basic glucemia, total cholesterol, cholesterol HDL, cholesterol LDL, , triglycerides.
Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 3 months.
Liver safety variables
時間枠:Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 3 months.
It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver.
Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 3 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年11月15日

一次修了 (実際)

2020年2月15日

研究の完了 (実際)

2020年4月30日

試験登録日

最初に提出

2020年4月8日

QC基準を満たした最初の提出物

2020年4月11日

最初の投稿 (実際)

2020年4月14日

学習記録の更新

投稿された最後の更新 (実際)

2020年5月21日

QC基準を満たした最後の更新が送信されました

2020年5月20日

最終確認日

2020年4月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • UCAMCFE-00013

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する